Coffee Consumption Associated with Lower Risk of Hepatocellular Carcinoma

Share this content:

the Cancer Therapy Advisor take:

A significant relationship has been found between coffee consumption and a reduced risk of developing hepatocellular carcinoma (HCC), but not with intrahepatic cholangiocarcinoma (ICC), according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.

Participants in this study included 1,212,893 participants (HCC: n = 860, ICC: n = 260) from the Liver Cancer Pooling Project.

Results showed that increased coffee consumption was associated with a reduced risk of HCC (HR > 3 cups/day vs. non-drinker, 0.73; 95% CI: 0.53, 0.99; Ptrend cups/day < 0.0001).  Women who consumed more than three cups of coffee per day had a significantly more reduced risk of HCC (54%) compared to men (HR, 0.46; 95% CI: 0.26, 0.81 compared to HR, 0.93; 95% CI: 0.63, 1.37, respectively; Pinteraction = 0.07).

Caffeinated coffee (HR > 3 cups/day vs. non-drinker, 0.71; 95% CI: 0.50, 1.01) displayed a stronger association with decreased HCC risk than decaffeinated coffee (HR, 0.92; 95% CI: 0.55, 1.54).

The study suggests further evaluations be conducted on specific coffee compounds and mechanisms to better understand their association with reduced HCC risk.

High versus low intake of coffee is associated with a reduced risk for endometrial cancer.
A significant relationship has been found between coffee consumption and a reduced risk of developing HCC.
Coffee consumption has been reported to be inversely associated with hepatocellular carcinoma (HCC), the most common type of liver cancer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs